Terms: = Lung cancer AND AKT2, PKBBETA, 208, ENSG00000105221, RAC-BETA, P31751, PRKBB AND Treatment
170 results:
1. Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.
Losurdo A; Dipasquale A; Giordano L; Persico P; Lorenzi E; Di Muzio A; Barigazzi C; Korolewicz J; Mehan A; Mohammed O; Scheiner B; Pinato DJ; Santoro A; Simonelli M
Front Immunol; 2024; 15():1323151. PubMed ID: 38298193
[TBL] [Abstract] [Full Text] [Related]
2. High-Frequency Jet Ventilation Versus Spontaneous Respiration for Percutaneous Cryoablation of lung Tumors: Comparison of Adverse Events and Procedural Efficiency.
Graur A; Mercaldo ND; Simon J; Alici C; Saenger JA; Cahalane AM; Vazquez R; Fintelmann FJ
AJR Am J Roentgenol; 2024 Apr; 222(4):e2330557. PubMed ID: 38264999
[No Abstract] [Full Text] [Related]
3. Charcot neuroarthropathy in persons with diabetes: It's time for a paradigm shift in our thinking.
Wukich DK; Frykberg RG; Kavarthapu V
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3754. PubMed ID: 38069459
[TBL] [Abstract] [Full Text] [Related]
4. Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study.
Chalhoub IG; Boulos RT; Dagher YG; El Helou S; Haifa KG; Atallah B; Nasr F; Kassab I; Chahine MN
Medicine (Baltimore); 2023 Sep; 102(39):e34562. PubMed ID: 37773843
[TBL] [Abstract] [Full Text] [Related]
5. Integrating Network Pharmacology and Experimental Validation to Explore the Effects and Mechanisms of Qinghao Biejia Decoction and Its Active Compound Artemisinin B Against Non-Small-Cell lung cancer.
Ye Y; Yang Y; Yan L; Zhou L; Yu S; Du Q; Dong X; Yuan Q; Shan L; Guo L
Drug Des Devel Ther; 2023; 17():2461-2479. PubMed ID: 37637262
[TBL] [Abstract] [Full Text] [Related]
6. Graph-based automatic detection and classification of lesion changes in pairs of CT studies for oncology follow-up.
Rochman S; Szeskin A; Lederman R; Sosna J; Joskowicz L
Int J Comput Assist Radiol Surg; 2024 Feb; 19(2):241-251. PubMed ID: 37540449
[TBL] [Abstract] [Full Text] [Related]
7. First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell lung cancer with ALK Rearrangement: Real-World Data.
Jeon Y; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2024 Jan; 56(1):61-69. PubMed ID: 37448121
[TBL] [Abstract] [Full Text] [Related]
8. NSCLC patients with a changing T grade after operation may represent a special subset of tumor staging.
Feng KP; Fu K; Xu C; Ding C; Zhu XY; Pan B; Jia XY; Zhao J; Li C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9991-9998. PubMed ID: 37258719
[TBL] [Abstract] [Full Text] [Related]
9. Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.
Tan X; Wang S; Xia H; Chen H; Xu J; Meng D; Wang Z; Li Y; Yang L; Jin Y
Invest New Drugs; 2023 Jun; 41(3):463-472. PubMed ID: 37140694
[TBL] [Abstract] [Full Text] [Related]
10. Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients.
Kadys A; Gremke N; Schnetter L; Kostev K; Kalder M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7319-7326. PubMed ID: 36920565
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
Wang N; Zhao L; Zhang D; Kong F
Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
[TBL] [Abstract] [Full Text] [Related]
12. [Retrospective analysis and a cross-sectional questionnaire survey of lung cancer concomitant with interstitial lung disease].
Liu XN; Li J; Chen RX; Shao C; Huang H; Xu X; Zhang MZ; Wang ZJ; Xu Z
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Dec; 45(12):1192-1198. PubMed ID: 36480849
[No Abstract] [Full Text] [Related]
13. Clinical outcomes of curative surgical resection of peritoneal metastasis in patients with colorectal cancer: A long-term follow-up study.
Bang K; Kim JE; Kim TW; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Hong YS
Cancer Med; 2023 Feb; 12(3):2861-2868. PubMed ID: 36069152
[TBL] [Abstract] [Full Text] [Related]
14. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract] [Full Text] [Related]
15. Interstitial lung Abnormalities in Patients With Locally Advanced Esophageal cancer: Prevalence, Risk Factors, and Clinical Implications.
Tseng SC; Hino T; Hatabu H; Park H; Sanford NN; Lin G; Nishino M; Mamon H
J Comput Assist Tomogr; 2022 Nov-Dec 01; 46(6):871-877. PubMed ID: 35995596
[TBL] [Abstract] [Full Text] [Related]
16. MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study.
Wang N; Zhu Y; Wu Y; Huang B; Wu J; Zhang R; Fan J; Nie X
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3219-3228. PubMed ID: 35904603
[TBL] [Abstract] [Full Text] [Related]
17. Prognosis of Patients with Bronchopulmonary Neuroendocrine Neoplasms in a Tertiary Neuroendocrine Tumor Centre of Excellence.
Rewitz KS; Grønbæk H; Tabaksblat EM; Dahl Baunwall SM; Dam G
Neuroendocrinology; 2022; 112(12):1214-1224. PubMed ID: 35671706
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Features of lung-Recurrent Hormone-Sensitive Prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of open versus minimally invasive surgery in the treatment of thoracolumbar metastases.
Ntilikina Y; Collinet A; Tigan LV; Fabacher T; Steib JP; Charles YP
Orthop Traumatol Surg Res; 2022 Jun; 108(4):103274. PubMed ID: 35331924
[TBL] [Abstract] [Full Text] [Related]
20. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract] [Full Text] [Related]
[Next]
